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Abstract
Background: Evidence suggests that the inflammatory events in the acute phase of spinal cord injury (SCI)
exacerbate the initial trauma to the cord leading to poor functional recovery. As a result, minimizing the
detrimental aspects of the inflammatory response after SCI is a promising treatment strategy. In this regard,
immunoglobulin G (IgG) from pooled human serum is a promising treatment candidate. Due to its putative,
though poorly characterized immuno-modulatory effects, IgG has been used clinically to treat neuroinflammatory
disorders such as Guillain-Barré syndrome, but its effects in neurotrauma remain largely unexplored.
Methods: This study examines the potential neuroprotective effects of IgG in a well-characterized cervical model of
SCI. Female Wistar rats were subject to moderate-severe clip compression injury at the C7-T1 level. IgG (0.4 g/kg) or
saline was injected intravenously to randomly selected animals at 15 min post SCI. At several time points post SCI,
biochemical assays, histology and immunohistochemistry analyses, and neurobehavioral assessments were used to
examine the neuroprotective effects of IgG at the molecular, cellular, and neurobehavioral levels.
Results: We found that intravenous treatment of IgG following acute clip-compression SCI at C7-T1 significantly
reduced two important inflammatory cytokines: interleukin (IL)-1β and IL-6. This early reduction in pro-inflammatory
signaling was associated with significant reductions in neutrophils in the spinal cord and reductions in the
expression of myeloperoxidase and matrix metalloproteinase-9 in the injured spinal cord at 24 h after SCI. These
beneficial effects of IgG were associated with enhanced tissue preservation, improved neurobehavioral recovery as
measured by the BBB and inclined plane tests, and enhanced electrophysiological evidence of central axonal
conduction as determined by motor-evoked potentials.
Conclusion: The findings from this study indicate that IgG is a novel immuno-modulatory therapy which shows
promise as a potential treatment for SCI.
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Introduction
Spinal cord injury (SCI) consists of two defined injury
processes termed the ‘primary’ and ‘secondary’ injury [1-
3]. The primary injury is caused by mechanical trauma
to the spinal cord. The secondary injury involves a cas-
cade of cellular and molecular events that leads to the
destruction of spinal tissue integrity beyond the site of
injury and results in sensory and motor deficits [2,4-6].
While the initial mechanical trauma causes immediate
tissue destruction at the injury site, a myriad of neuro-
toxic substances during the secondary injury event de-
struct tissue in the penumbra region in a delayed and
progressive fashion.
Neuroinflammation is implicated in orchestrating the
secondary injury cascade after SCI [7,8]. Neutrophils,
microglia, and macrophages can exacerbate SCI with
their cellular products including pro-inflammatory cyto-
kines, matrix metalloproteinases (MMPs), and reactive
oxygen radicals. Many different pharmacological agents
have been examined for their efficacy in attenuating
inflammation-mediated damage after SCI, including
methylprednisolone [9-11], minocycline [12-14], anti-
CD11d/CD18 antibodies [15-17], neutrophil elastase in-
hibitor [18], secretory leukocyte protease inhibitor [19],
and depletion of peripheral macrophages [20].
While a large number of immuno-modulatory agents
have been examined at the preclinical stage, few studies
have shown robust enough effects for these agents to be
considered for clinical translation [21]. Only methylpred-
nisolone has demonstrated some level of efficacy in im-
proving patients’ functional recovery in Phase III clinical
trials [22]. However, the effectiveness of methylpredniso-
lone treatment is modest and is associated with
increased susceptibility to infections and wound-related
complications in SCI patients [23,24]. Thus there is an
impetus to find a safe and effective therapy that attenu-
ates inflammation-mediated damage and improves
patients’ functional recovery after SCI.
Immunoglobulin G (IgG) is a potential treatment can-
didate. Intravenous use of IgG exhibits many immuno-
modulatory properties and has been used clinically to
treat several autoimmune diseases [25]. Currently, IgG is
being investigated as an immuno-modulatory therapy in
many neurological diseases that have a similar pathobiol-
ogy to SCI, such as multiple sclerosis and stroke [26,27].
With the exception of one preliminary report describing
how intraperitoneal injection of IgG immediately after
SCI reduced myeloperoxidase activity in the injured
spinal cord, the neuroprotective effects and the
immuno-modulatory mechanisms of IgG in neuro-
trauma are currently unclear [28].
In this study, we examined a potential immuno-
modulatory mechanism of IgG in the context of SCI
and carried out a detailed characterization of IgG’s
neuroprotective properties at the molecular, cellular, and
neurobehavioral levels. We hypothesized that IgG treat-
ment after SCI would attenuate inflammation-mediated
damage and improve functional recovery. We provide
novel evidence that IgG attenuates post-injury rises in
interleukin (IL)-1β and IL-6, reduces the extent of neutro-
phil invasion and post-traumatic levels of MMP-9 and
myeloperoxidase, is associated with perilesional tissue
sparing, and promotes neurobehavioral and electrophysio-
logical evidence of functional recovery.
Material and methods
Experimental and control groups
This study used 135 female Wistar rats (250 to 300 g)
from Charles River and followed the animal-use protocol
approved by the Animal Use Committee (AUC) of the
University Health Network (#979) for all procedures. All
rats underwent a C7-T2 laminectomy and were then
randomly and blindly assigned to three groups (sham,
saline, and IgG). A 35-g modified aneurysm clip was ap-
plied extradurally to animals in the saline and IgG
groups at the level C7-T1 for 60 s to cause a moderate
to severe spinal cord injury [29,30]. The spinal cords of
sham animals were not injured. Animals were given
1 mL of buprenorphine (0.05 mg/kg) and 5 mL of saline
immediately and subsequently every 12 h for 3 days after
surgery.
IgG (I4506) from pooled human serum was purchased
from Sigma Aldrich. After dissolving 500 mg of IgG in
4 mL of sterile saline solution (0.9% NaCl, Baxter), a sin-
gle bolus of IgG at a dosage of 0.4 g/kg was injected
intravenously through the tail-vein at 15 min after SCI.
Control animals were injected intravenously through the
tail-vein with 1 mL of sterile saline (0.9% NaCl). The
dosage of 0.4 g/kg was chosen based on the reported
dosage by Gok et al. and based on the clinical dosages
that are currently used to treat Guillain-Barré syndrome
and other autoimmune disorders [25,28]. There was no
noticeable difference in the general behavior and appear-
ance of animals that received either IgG or saline. There
was also no difference in mortality rate between saline
and IgG-treated animals. All assessors were blinded to
the treatment groups throughout the study.
Biochemical analyses
Following SCI, animals were sacrificed at 4 h for multi-
plex enzyme-linked immunosorbant assays (ELISA) and
at 24 h for western blot and myeloperoxidase (MPO) ac-
tivity analyses. Each animal was overdosed with pento-
barbital and perfused with 180 mL of iced-cold saline
(0.9% NaCl). The spinal cord was isolated in ice-cold
Ringer’s solution and the meninges were removed. A
0.5 cm length of the spinal cord centered at the injury
epicenter was dissected, immediately frozen with liquid
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nitrogen and crushed with a frozen mortar and pestle.
The tissue was then stored at −80°C until use.
Myeloperoxidase activity assay
Myeloperoxidase (MPO) activity was determined using a
MPO fluorometric kit available from Assay Designs
(Enzo Life Sciences) according to manufacturer instruc-
tions. A total of 21 animals were used in this experiment
(four sham, nine saline-treated, and eight IgG-treated
animals). Briefly, cellular membranes were disrupted and
blood was removed by homogenizing spinal cord tissue
in the provided homogenization buffer (without deter-
gent) containing 10 mM N-Ethylmaleimide. The samples
were then centrifuged at 4°C at 12,000 g for 20 min, and
the supernatant was removed. MPO was released from
granules in pelleted material by homogenizing in
solubilization buffer containing 0.5% of the detergent
hexadecyltrimethylammonium (HTA-Br) (w/v) and also
by exposing the mixture to two freeze/thaw cycles. The
samples were then centrifuged at 8,000 g for 20 min at
4°C. The resultant supernatants were used in the assay.
A Perkin-Elmer plate reader measured the fluorescence
intensity, with excitation wavelength at 530 nm and
emission wavelength at 590 nm. A calibration curve run
concurrently with the samples was used to determine
the MPO activity from the measured relative fluores-
cence intensity (RFU).
Western blot
A total of 21 animals were also used in this experiment
(four sham, nine saline-treated, and eight IgG-treated
animals). Spinal cord tissue was solubilized in 400 μL of
RIPA buffer (25 mM Tris–HCl pH 7.6, 150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS; Thermo
Fisher) containing a cocktail of phosphatase and prote-
ase inhibitors. Protein concentration of each sample was
measured using the Modified Lowry method [31,32]. All
western blot reagents were purchased from Bio-Rad un-
less otherwise stated. An equal amount of protein (20 μg
of total protein) per sample was separated using a 12%
SDS-PAGE gel. Following electrophoresis, the gel was
transferred onto a nitrocellulose membrane overnight.
The membrane was then washed in 0.2% tween tris buf-
fered saline (TBS-T) and blocked for 1 h in TBS-T+ 5%
milk. Primary antibodies were incubated overnight at
4°C, and the secondary antibody incubation step was
accomplished at room temperature for 1 h (Table 1 lists
the primary and secondary antibodies used for western
blot analysis). The membrane was washed with TBS-T
three times for 5 min each time in between each anti-
body incubation step. Enhanced ChemiLuminescence
(ECL; Perkin Elmer) substrate for horseradish peroxidase
(HRP) was used to detect the signal. Densitometry ana-
lysis was accomplished using Quantity One software
(Biorad).
Enzyme-Linked Immunosorbant Assay (ELISA) analysis
Spinal cord homogenates of 19 animals (four sham,
seven saline-treated, and eight IgG-treated animals) were
generated using the same method described for the
western blot procedure. Inflammatory cytokine (TNF-α,
IL-1β, and IL-6) and chemokine (CINC-1 and MCP-1)
levels in spinal cord homogenates were determined
using multiplex ELISA. The ELISA procedure utilized
was that of Eve Technologies (Calgary, AB, Canada)
using plates commercially available from Millipore.
Histological and immunohistochemical analysis
Animals were sacrificed at 24 h after SCI for immuno-
histochemical analysis and at 6 weeks after SCI for histo-
logical analysis. Each animal was overdosed with
pentobarbital and then perfused with 60 mL of ice-cold
phosphate-buffered saline (PBS) and 180 mL of para-
formaldehyde (4% w/v in PBS, pH 7.4). The spinal cord
of each animal was dissected and post-fixed overnight
with 10% sucrose 4% para-formaldehyde PBS solution.
The spinal cord was then cryo-protected in 20% sucrose
PBS solution. The spinal cord tissue (1.0 cm centering
on the injury epicenter) was embedded in tissue-tek and
stored at −80°C. Spinal cords embedded into tissue-tek
were cryosectioned at 20 μm thickness. Tissue sections
were mounted on glass slides and stored at −80°C.
Cellular localization and tissue distribution of IgG at 24 h
after SCI
Tissue sections from nine animals (three sham, three sa-
line-treated, and three IgG-treated animals) were incu-
bated in 1% SDS in PBS for antigen-retrieval and washed
in between staining steps at least three times for at least
10 min each. Primary antibodies were incubated at 4°C
Table 1 List of primary and secondary antibodies used for western blot analysis
Antibody Host Company Dilution Duration
Anti-rat β-actin Mouse Chemicon (MAB1501R) 1:500 Overnight 4°C
Anti-rat matrix metalloproteinase (MMP)-9 Rabbit Chemicon (AB19016) 1:1,000 Overnight 4°C
Anti-rabbit IgG horseradish peroxidase (HRP) Goat Jackson Lab (11-035-144) 1:5,000 1 h RT
Anti-mouse IgG horseradish peroxidase (HRP) Goat Sigma (A-3682) 1:2,000 1 h RT
Antibody concentrations and incubation conditions are listed.
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overnight, and secondary antibodies were incubated at
room temperature for 1 hour. Secondary antibody alone
(no primary antibody) served as negative control. The
same exposure and detector settings were used to ac-
quire all images. Table 2 lists the primary and secondary
antibodies used for the immunohistochemistry analyses.
Stereological quantification of neutrophil infiltration
Tissue sections from 16 animals (four sham, seven sa-
line-treated, and five IgG-treated animals) were stained
following a similar protocol as above. Tissue sections
were systematically sampled at every 240 μm over a dis-
tance of 3,000 μm (total of 14 tissue sections), which
were centered at the lesion epicenter in each animal.
Neutrophils were stained with anti-PMN (polymorpho-
nuclear cells; Cedarlane Labs) primary antibodies and
probed with anti-rabbit AlexaFluor 488 secondary anti-
bodies. Neutrophils were quantified stereologically using
the StereoInvestigator Software. Every cell that was posi-
tively stained with anti-PMN antibodies was cross-
checked with a fluorescence nuclear stain signal, DAPI
(40, 6-diamidino-2-phenylindole) ensuring that every
counted cell had a nucleus.
Luxol-fast blue/haematoxylin-eosin staining for histological
analysis
At 6 weeks following injury, spinal cord tissue sections
from 18 animals (four sham, seven saline-treated, and
seven IgG-treated animals) were systematically sampled
at every 120 μm over a distance of 4,000 μm (34 tissue
sections per animal). Tissue sections were stained with
luxol-fast blue (LFB) overnight at 56°C. Haematoxylin
was used to stain nuclei and eosin was used as a coun-
ter-stain. After staining, tissue sections at which the in-
jury epicenter localized were selected using the following
criteria: (1) the largest area of scar and cavity relative to
other tissue sections of the same animal; and (2) the
smallest area of white matter and/or grey matter. After
the injury epicenter center was located, other tissue sec-
tions were selected with respect to the injury epicenter.
Tissue sections were analyzed using the Cavalieri Probe
(StereoInvestigator software), which allowed the experi-
menter to manually measure the area of interest on each
tissue section.
The following criteria ensured consistency during
histological analysis: (1) cavity and scar area consisted of
any area on the tissue section that was surrounded by
scar tissue or appeared to be devoid of tissue; (2) white
matter area consisted of any tissue region that appeared
blue due to LFB staining; (3) grey matter consisted of
any tissue region that appeared red due to eosin staining;
and (4) preserved tissue area was the sum of the grey
matter and white matter area. Scar tissue comprised any
tissue area that had a fibrous and inconsistent tissue
matrix. The percentage of scar and cavity area was cal-
culated using the following formula:
%of scar and cavity of tissue section Y
¼ area of scar and cavity of tissue section Y
total area of section Y
The percentage of preserved tissue was calculated
using the following formula:
%of preserved tissue of section X
¼ area of white and grey matter of tissue section X
total area of section X
Assessment of functional recovery
Neurobehavioral assessment
A total of 31 animals (four sham, 13 saline, and 14 IgG-
treated animals) were used for the neurobehavioral as-
sessment and electrophysiological recordings. We
assessed functional recovery using the inclined plane
and the Basso Beattie Bresnahan (BBB) tests. The
inclined plane test is an integrated neurobehavioral test
that evaluates forelimb, hind-limb, and trunk control.
The inclined plane test was originally described by Rivlin
and Tator [33], and has been validated as a sensitive
measure of injury at C7-T1 [30]. Performance on the
inclined plane test correlates with the number of
remaining axons belonging to non-pyramidal tracts in-
cluding the rubrospinal, vestibulospinal, and raphespinal
tracts [30,34]. The BBB test was used to make weekly
assessments of the animals’ hind-limb function [35].
Two blinded observers evaluate the animal’s hind-limb
function for 4 consecutive minutes and assign a score
based on a 21-point locomotor rating system.
Table 2 List of primary and secondary antibodies used for immunohistochemistry
Antibody Host Company Dilution Duration
Anti-rat ionized calcium binding adapter molecule (Iba)-1 Rabbit Wako (019–19741) 1:300 Overnight 4°C
Anti-rat endothelial cell antibody (RECA-1) Mouse Serotec (MCA970R) 1:100 Overnight 4°C
Anti-human IgG-TRITC Goat Chemicon (AP504R) 1:300 1 h RT
Anti-rabbit IgG AlexaFluor 488 Goat Invitrogen (A11034) 1:300 1 h RT
Anti-mouse IgG AlexaFluor 488 Goat Invitrogen (A11001) 1:300 1 h RT
Antibody concentrations and incubation conditions are listed.
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Electrophysiology
Motor-evoked potentials (MEPs) indicate descending
motor pathway function, and the validity of this tech-
nique in animal models of SCI has been well demon-
strated [36]. At 6 weeks after SCI, MEPs were recorded
from 17 randomly selected animals (three sham, seven
saline-treated, and seven IgG-treated animals), which
had previously been used in the neurobehavioral assess-
ment, under isofluorane anesthesia. Two stainless-steel
needle electrodes were inserted into the tibialis for
recording EMG signals. After removing inter-laminar
ligaments between C1, C2, and C3, two pairs of 1.0 mm
ball recording electrodes were positioned extradurally
over the spinal cord, under the vertebral arch of C3. A
constant current stimulus of 0.1 ms in duration and
2.0 mA in intensity was applied at a rate of 0.13 Hz to
the dorsum at either C1 or C3. At a bandwidth of 10 to
3,000 Hz, a total of 500 MEPs were averaged and repli-
cated using an electrodiagnostic device (Dantac Keypoint
Portable, Denmark). Spinal axonal conduction velocity
was calculated by dividing the distance between the
stimulating electrodes by the difference between the
peak latencies of distal and proximal stimuli.
Statistical analysis
All statistical analyses were completed using SigmaStat
Software. One-way analysis of variance (ANOVA) fol-
lowed by a Bonferroni post-hoc test was used to deter-
mine the difference between treatments with regard to
the biochemical, immunohistochemical, molecular and
electrophysiology analyses. A two-way ANOVA followed
by Bonferroni post-hoc test was used to determine sig-
nificant differences between treatments in BBB and
inclined plane tests over several time points. Since
MMP-9 expression was not detectable in the sham
group, the Student t-test was used to test the difference
between saline and IgG-treated animals. All data are
reported as mean± SEM. Differences were considered
significant at P <0.05.
Results
Systemically delivered IgG enters the injured spinal cord
and co-localizes with astrocytes
Fluorescence microscopy was used to show that IgG was
present in the spinal cord of the injured rat 24 h follow-
ing injury (Figure 1A). IgG (shown in red) could be seen
caudal and rostral to the injury site and in the white and
grey matter. The fluorescence signal associated with
IgG’s presence was very weak in the non-injured spinal
cord with IgG injection (Figure 1A, right panel). This is
supported with confocal microscopy (Figure 1B). Images
were acquired using a 60X objective at approximately
1000 μm caudal to the injury site. At 24 h after injection,
IgG was found outside the vasculature (marked by
RECA-1 positive staining) in the spinal cords of injured
animals. In contrast, non-injured animals with IgG injec-
tion contained no parenchymal IgG (Figure 1B, right
panel). This suggests that SCI enabled IgG to cross the
blood-spinal cord barrier (BSCB).
Microglia and astrocytes are two important CNS cell
types involved in the orchestration of the inflammatory
response [37,38]. Having demonstrated that IgG appears
to cross the BSCB at 24 h after SCI, we assessed whether
IgG would co-localize with microglia and astrocytes
using confocal microscopy. Iba-1 is a marker for micro-
glia/macrophages. Since monocytes do not infiltrate the
injured spinal cord until 2 to 3 days after SCI, most of
the Iba-1 positive cells are likely microglia. IgG (red), al-
though in the same vicinity, did not co-localize with Iba-1
(green) positive cells in IgG-injected animals (Figure 1C).
Importantly, IgG was not observed in saline injected ani-
mals even though the secondary antibody specific to
human IgG was applied to these sections (Figure 1C,
lower panel).
Astrocytes were stained with anti-glial fibrillary acid
protein (GFAP). We observed co-localization between
GFAP (green) and IgG (red) in animals with IgG treat-
ment (Figure 1D). Again, there was no IgG signal in sa-
line injected animals, as expected (Figure 1D, bottom
panel). This observation suggests potential interaction
between IgG and astrocytes in IgG-treated animals.
Intravenous IgG significantly reduces neutrophil infiltration
Neutrophils (which produce MPO) represent an import-
ant component of the innate immune response and infil-
trate the injured spinal cord maximally at 24 h after SCI
[7]. At 24 h after SCI, MPO activity was found to have
significantly increased in animals with SCI compared to
sham animals (Figure 2A). The MPO activity in the
injured spinal cord of IgG-treated animals was signifi-
cantly lower than the MPO activity in saline-treated ani-
mals (one-way ANOVA P <0.001; Bonferroni post-hoc
test P= 0.009).
Next, we used immunohistochemistry and stereology
to quantify the number of neutrophils in the injured
spinal cord at 24 h after SCI. Neutrophils were observed
in both saline and IgG-treated SCI animals (Figure 2B
middle and right panels) but not in sham animals
(Figure 2B, left panel). Figure 2D demonstrates that sig-
nificantly fewer neutrophils were counted in IgG-treated
animals compared to saline controls (one-way ANOVA
P < 0.001; Bonferroni post-hoc test P= 0.011).
Intravenous IgG significantly reduces MMP-9 expression
MMP-9 is a matrix enzyme that is produced by neutro-
phils and microglia. During inflammation, MMP-9 helps
neutrophils cross the endothelial wall to the injury site
by degrading the collagen matrix of the basoendothelial
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wall (Delclaux, 1996). At 24 h after SCI, we observed
that the level of MMP-9 increased significantly in the
injured spinal cord of saline-treated animals (Figure 3 A
and B). However, MMP-9 expression was not detected
using western blot in sham animals. Densitometric and
statistical analysis showed that IgG treatment signifi-
cantly reduced MMP-9 expression compared to the sa-
line controls (t-test P= 0.004).
Intravenous IgG treatment significantly reduces
pro-inflammatory cytokine and chemokine levels in the
injured spinal cord
Pro-inflammatory cytokines such as TNF-α, IL-1β, and
IL-6 have been shown to mediate the inflammatory re-
sponse in many conditions including SCI. Using multi-
plex ELISA, we examined the expression of cytokines
and chemokines in spinal cord homogenates at 4 h fol-
lowing injury. Expression of these inflammatory media-
tors was significantly higher in injured animals
compared to sham animals. Figure 4A demonstrates that
although TNF-α levels in IgG-treated animals were
lower than in saline-treated animals, the difference was
not statistically significant (one-way ANOVA P <0.01;
Bonferroni post-hoc test P= 0.084). However, IL-1β
(Figure 4B) and IL-6 (Figure 4C) levels in IgG-treated
animals were significantly lower than in saline control
animals. These data suggest that IgG treatment is asso-
ciated with significant reductions in the level of IL-1β
(one-way ANOVA P <0.001; Bonferroni post-hoc test
P= 0.007) and IL-6 (one-way ANOVA P <0.001; Bonfer-
roni post-hoc test P= 0.003) in the injured spinal cord at





Injured - IgG Injected
Injured - IgG Injected
Non-injured Sham IgG Injected
Non-injured Sham IgG Injected
Dapi
Dapi
Figure 1 IgG crosses the blood spinal cord barrier and associates with astrocytes. (A) Representative fluorescence images showing the
presence of IgG in the spinal cords of an injured rat (left) and a non-injured rat (right). (B) Vessels were stained with RECA-1 (green) and IgG was
labeled with a human specific IgG secondary antibody (red). Confocal images demonstrate IgG was able to cross the blood-spinal cord barrier in
injured animals (left panel) but not in non-injured animals (right panel). (C) Representative confocal images of microglia/macrophages
(Iba-1; green) and IgG (red). IgG was observed in the parenchyma surrounding cells marked by Iba-1 and DAPI (blue). Although IgG was in the
vicinity of Iba-1 positive cells, co-localization between IgG and Iba-1 was not observed. (D) Representative confocal images of astrocytes (GFAP;
green) and IgG (red). IgG was observed in the parenchyma surrounding and in the cell soma of GFAP positive astrocytes. The co-localization of
IgG and astrocytes suggests potential interaction between IgG and astrocytes. Note that an IgG-positive signal was not observed in the spinal
cord of rats injected with saline. Confocal images (B-D) were taken from the boxed area, and scale bars represent 50 μm in length.
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Since IgG treatment is associated with significant
reductions in MPO activity, IL-1β, and IL-6 levels, we
examined whether IgG had any effect on the level of
neutrophil and macrophage chemoattractants - CINC-1
(Figure 4D) and MCP-1 (Figure 4E), respectively. SCI
increased the expression of these inflammatory media-
tors relative to sham animals. IgG treatment significantly
reduced MCP-1 protein levels at 4 h after SCI relative to
saline controls (one-way ANOVA P <0.001; Bonferroni
post-hoc test P= 0.03). However, IgG did not signifi-
cantly reduce the expression of CINC-1 compared to
saline controls (one-way ANOVA P <0.001; Bonferroni
post-hoc test P= 0.38).
Intravenous treatment with IgG significantly reduces scar
and cavitation in the injured spinal cord and enhances
preserved neural tissue
In order to determine whether attenuation of the inflam-
matory response at 4 h and 24 h after SCI affects the
amount of tissue sparing and extent of scarring and cavi-
tation, we performed spinal cord histological analyses at








Figure 2 IgG reduces neutrophil extravasation. (A) Myeloperoxidase (MPO) activity was detected in sham (n= 4), intravenous saline (saline,
n= 9), and intravenous IgG (IgG, n= 8) groups. MPO was used to indirectly measure the presence of neutrophils 24 h after SCI. IgG-treatment
significantly reduced MPO activity relative to saline control (ANOVA P <0.05, Bonferroni post-hoc test P= 0.009). (B) Representative fluorescence
images demonstrate neutrophil distribution at the injury epicenter in the spinal cord at 24 h post SCI (PMN; green). Neutrophils were observed in
both saline and IgG-treated animals. (C) A representative confocal image of neutrophils (PMN; green) and DAPI (blue) was taken from the
indicated area (smaller box), and the scale bar represents 75 μm in length. (D) Stereological cell counts demonstrated significantly fewer
neutrophils in IgG-treated animals relative to saline control injected animals across 3,000 μm of the injured spinal cord (one-way ANOVA P <0.001;
Bonferroni post-hoc test P= 0.011). Error bars represent SEM.
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spinal cords had the largest area of scar and cavity and
the smallest area of tissue sparing (Figure 5 A and B).
Representative H&E/LFB images are shown in
Figure 5C. As the distance from the injury epicenter
increased, the area of scar and cavity decreased and the
area of preserved tissue increased. There was an overall
treatment effect in the scar/cavitation size and amount
of tissue sparing in the IgG-treated animals (two-way
ANOVA P= 0.013 for each). IgG-treated animals had
significantly less scarring at the injury epicenter (0 μm)
and at distances 240 μm, 360 μm, 480 μm, 600 μm,
720 μm, and 840 μm rostral to the injury epicenter
(Bonferroni post-hoc test P < 0.05 for each distance;
Figure 5A). At 6 weeks after SCI, IgG-treated animals
had significantly more preserved tissue compared to the
saline-treated animals at the injury epicenter (0 μm) and
at distances 240 μm, 360 μm, 480 μm, 600 μm, 720 μm,
and 840 μm rostral to the injury epicenter (Bonferroni
post-hoc test P <0.05 for each distance; Figure 5B).
Intravenous IgG treatment increases neurobehavioral
recovery after spinal cord injury
Functional recovery, as tested by the BBB (Figure 6A)
and the inclined plane test (Figure 6B), was significantly
greater in IgG-treated animals compared to the saline
control group. Sham animals displayed no functional
deficits throughout the 6-week period and thus scored
21 on the BBB scale. The differences in BBB scores be-
tween IgG- and saline-treated animals were statistically
significant at weeks 2, 3, 5, and 6 (two-way ANOVA
P <0.001; Bonferroni post-hoc test P <0.001, P= 0.015,
P= 0.031, and P= 0.017, respectively). The BBB results
suggest that IgG treatment is associated with increased
hind-limb functional recovery compared to saline con-
trols. More specifically, animals in the IgG-treated group
on average had extensive movement in all three joints
and some level of weight support, while saline-treated
animals on average had extensive movement in all three
joints without any weight support. IgG-treated animals
also displayed a greater recovery than saline-treated ani-
mals in the inclined plane test from week 3 to week 6
(two-way ANOVA P <0.001; Bonferroni post-hoc test
week 5 P= 0.012 and week 6 P <0.001). To support the
neurobehavioral improvement, motor-evoked potentials
were recorded in injured spinal cords at 6 weeks follow-
ing SCI (Figure 6C). Conduction velocity in both the
IgG and vehicle control group was significantly reduced
compared to uninjured sham rats (one-way ANOVA
P <0.05; Bonferroni post-hoc test P <0.01). IgG-treated
animals had significantly faster conduction velocity com-
pared to saline control animals (P= 0.03). Representative
MEP tracings for each group are shown.
Discussion
In this study, we present a novel application of IgG in at-
tenuating the effects of inflammation-mediated damage
and improving neurobehavioral recovery after cervical
SCI. More specifically, IgG-treatment is associated with
a significant reduction in the level of pro-inflammatory
cytokines and chemokines (IL-1β, IL-6, and MCP-1), in
the level of cytotoxic enzymes (MMP-9 and MPO), and
the level of neutrophil infiltration. Our results are con-
sistent with reported findings from other laboratories
which have indicated that pro-inflammatory cytokines
and neutrophils can potentiate the initial injury follow-
ing SCI [20,39,40]. Although the potential use of IgG for
traumatic SCI was previously reported by Gok et al.
[28], Gok and colleagues did not report the neuroprotec-
tive mechanism and any long-term neurobehavioral
benefit of IgG treatment. Our current manuscript
Figure 3 IgG reduces MMP-9 expression. (A) Matrix metalloproteinase-9 (MMP-9) expression was determined by western blot analysis at 24 h
after SCI. Three treatment groups were studied including laminectomy only (sham, n= 4), intravenous saline (saline, n= 9), and intravenous IgG
(IgG, n= 8). IgG treatment was associated with a significant reduction in MMP-9 level in the injured spinal cord (P= 0.004). Error bars represent
SEM. (B) A representative western-blot of MMP-9 is shown. β-actin was used as a loading control.
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suggests a potential immuno-modulatory mechanism of
IgG and provides a more detailed demonstration of the
immuno-modulatory effects of IgG at the molecular, cel-
lular, and neurobehavioral level.
IgG treatment significantly reduces the level of neutrophil
infiltration and cytotoxic enzymes in the injured
spinal cord
Neutrophils, which represent an important component
of the innate immune response, infiltrate the spinal cord
within hours of injury, and maximal cell numbers are
reached at 24 h after SCI [7]. Neutrophils can increase
the extent of tissue injury after SCI by producing react-
ive oxygen species (ROS) and reactive nitrogen species
(RNS) [41-43] that can damage proteins, DNA, and
lipids. Neutrophils can further increase the extent of the
inflammatory response by producing pro-inflammatory
mediators such as TNF-α, IL-1β, and IL-8 [44]. MMP-9
secreted by neutrophils can degrade the collagen matrix
of the blood-spinal cord barrier and increase leukocyte
infiltration [45,46]. Blockade of neutrophil infiltration
using various strategies has been demonstrated to re-
duce oxidative damage and to improve neurobehavioral
recovery in several rat models of SCI [17,18,39,40]. In
the current study, we found that intravenous IgG treat-
ment was associated with a significant reduction in
MPO activity at 24 h after SCI (Figure 2A). MPO is an
enzyme produced by neutrophils and stored in the azur-
ophilic granules, and as such, MPO activity was used as
an indirect measure of neutrophil presence in the
injured spinal cord [47]. Our finding is consistent with a
previous report by Gok et al., in which IgG was asso-
ciated with a significant reduction in MPO activity when







Figure 4 IgG reduces IL-1β, IL-6, and MCP-1 expression. Expression of cytokines (TNF-α, IL-1β and IL-6) and chemokines (MCP-1 and CINC-1)
at 4 h after SCI was determined with ELISA in the spinal cord homogenates of sham, saline, and IgG-treated animals. SCI resulted in a significant
increase of all inflammatory mediators relative to non-injured sham animals. (A) There was no difference in TNF-α protein expression between
saline and IgG-treated animals (P= 0.084). (B) IgG treatment was associated with a significant reduction in IL-1β following SCI in rats (P= 0.007).
(C) IL-6 protein expression was significantly reduced in IgG-treated animals relative to saline controls (P= 0.003). (D) IgG treatment was associated
with a significant decrease in MCP-1 protein expression relative to saline controls (P= 0.003). (E) IgG treatment had no effect on the level of
CINC-1 after SCI relative to saline control injected animals (P= 0.38). Error bars represent SEM.
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SCI [28]. We also observed a significant reduction in
neutrophil infiltration to support the MPO data
(Figure 2B and C).
IgG treatment significantly reduces pro-inflammatory
cytokine and chemokine levels in the injured spinal cord
Immediately after SCI, a rapid increase in the levels of
TNF-α, IL-1β, and IL-6 is observed in the spinal cords
of humans and animal models of SCI [7,48-50]. It has
been suggested that these cytokines exacerbate the
initial damage and contribute to neurodegeneration
following CNS injury [51]. Following CNS injury, pro-
inflammatory cytokines play an important role in acti-
vating and recruiting leukocytes including neutrophils,
monocytes, and lymphocytes. Pro-inflammatory cyto-
kines promote leukocyte infiltration to the site of injury
by increasing the expression of vascular cell adhesion
molecules on the surface of endothelial cells [52,53] and
by regulating the expression and secretion of chemo-
kines [38,54,55]. IL-6 has previously been shown to
regulate the production of IL-8 and MCP-1 expression
in a mouse model of skin pouch inflammation [54]. Fur-
thermore, IL-1β has previously been shown to regulate
the production of CINC-1 and MCP-1 in a mouse model
of SCI via the IL-1R/MyD88 axis, and astrocytes were
shown to be the primary cellular source of the afore-
mentioned cytokines [38].
IgG treatment was associated with a significant reduc-
tion in IL-1β and IL-6 levels in the injured spinal cord.
This finding may explain why neutrophil infiltration is
attenuated upon intravenous administration of IgG after
SCI. In fact, previous studies in SCI have shown that
reductions in the expression level or disruption in the
signaling pathway of either TNF-α, IL-1β, or IL-6 is
associated with a significant reduction in neutrophil in-
filtration in SCI models as well as other models of acute
inflammation [38,54,56,57]. Along the same lines, if
TNF-α or IL-1β is injected into a non-injured spinal
cord or IL-6 is over-expressed in an injured spinal cord,
then leukocyte infiltration has been shown to be
enhanced [58-60]. Our findings suggest the observed re-
duction in neutrophil infiltration may be due to IgG’s
mechanism of action in reducing the level of pro-
inflammatory cytokines in SCI. In our future experi-
ments, using our established experimental paradigms,
we could employ antibodies to block Fc receptors as an
approach to elucidating the immuno-modulatory mech-
anism of IgG.
We observed that IgG treatment was associated with a
significant reduction in MCP-1 levels but not CINC-1.
In addition to astrocytes, endothelial cells have been
shown to co-localize with CINC-1 after SCI in the peri-
vascular region [18]. Currently, there is insufficient sci-
entific evidence describing the primary cellular source of
these chemokines and the signal transduction pathways
that regulate the production of these chemokines. The
lack of strong supporting evidence in the literature pre-
sents major challenges in outlining the relationship be-
tween IL-1β, IL-6, MCP-1, and CINC-1 in animal
models of SCI. The heterogeneity in species and injury
Figure 5 IgG reduces scar and cavity formation and preserves neural tissue. (A) The distribution of scar and cavity area over 4000 μm of
the injured spinal cords of sham (n= 4), saline (n= 7), and IgG (n= 7) animals was calculated at 6 weeks following injury. There was a treatment
effect in the area of cavitation and scar in IgG-treated animals (two-way ANOVA, P= 0.013). IgG-treated animals had significantly less scar and
cavity area at 600 μm (P= 0.012) and 720 μm (P= 0.042). (B) Preserved tissue (remaining grey and white matter) in injured spinal cords was
calculated. There was an overall treatment effect in the amount of tissue sparing in IgG-treated animals (two-way ANOVA, P= 0.015). IgG-treated
animals had significantly more preserved tissue compared to saline-treated animals at a distance of 600 μm (P= 0.002), 720 μm (P= 0.017), and
840 μm (P= 0.044) rostral to the injury epicenter. (C) Representative H&E/LFB images are shown. Error bars represent SEM.
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mechanisms of animal models of SCI make it difficult to
draw correlations between published findings and the
observations stemming from the present body of work.
Future experiments examining the cellular targets of IgG
and the cellular sources of cytokines and chemokines in
rats will illuminate the complex interaction and regula-
tion of cytokine and chemokine expression.
Although qualitative in nature, our immunohisto-
chemistry experiments using astrocyte and microglia as
specific markers provide valuable insights into the cellu-
lar target(s) of IgG in SCI. We observed that IgG only
co-localized with astrocytes and is associated with sig-
nificant reduction in the level of IL-1β and IL-6. Previ-











Figure 6 IgG increases neurobehavioral recovery and axonal function. (A) Hind-limb functional recovery was assessed weekly for 6 weeks
following SCI. Scores were assigned according to the Basso Beattie Bresnahan (BBB) Scale. Sham animals (n= 4) displayed no hind-limb functional
deficits and were given a score of 21. IgG treatment was associated with significant improvement in hind-limb functional recovery (two-way
ANOVA P <0.001). The differences in BBB scores between IgG- and saline-treated animals were statistically significant at weeks 2, 3, 5, and 6
(Bonferroni post-hoc test P <0.001, P= 0.015, P= 0.031, and P= 0.017, respectively). (B) The inclined plane test was used to assess functional
recovery of the saline (n= 13) and IgG (n= 14) groups. The inclined plane test measures the hind- and forelimb strength and coordination
necessary to maintain a horizontal position on an inclined plane. Larger inclined angles are associated with better functional recovery. At weeks 5
and 6, IgG-treated animals performed significantly better than saline-treated animals on the inclined plane test (two-way ANOVA P <0.001;
Bonferroni post-hoc test week 5 P= 0.012 and week 6 P <0.001). (C) Motor-evoked potentials (MEPs) were recorded in injured spinal cords at
6 weeks following SCI. Conduction velocity in both the IgG and vehicle control group was significantly reduced compared to uninjured sham rats
(one-way ANOVA P <0.05; Bonferroni post-hoc test P <0.01). IgG-treated animals demonstrated significantly faster conduction velocities compared
to saline control animals (P= 0.03). (E) Schematic diagram showing how MEPs was recorded in the injured spinal cords at 6 weeks following SCI.
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cytokines might explain why IgG had only a modest at-
tenuation in the level of TNF-α after SCI. Microglia/
macrophages and astrocytes are the major cellular
sources of TNF-α, IL-1β, and IL-6 immediately after SCI
[37]. The level of IL-1β but not TNF-α is maintained by
neutrophils and astrocytes at later time points after SCI
[37,48]. Although determining the exact cellular target
and the underlying mechanism of IgG is beyond the
scope of this study, the selective reduction of cytokine
expression and the specific astrocytic co-localization of
IgG suggest some degree of cellular specificity in IgG’s
mechanism of action. Although we did not observe co-
localizations between IgG and Iba-1 positive cells in this
study, we cannot rule out the potential interaction be-
tween microglia and IgG in the acute phase as well as
the sub-acute phase of SCI. The underlying mechanism
and the molecular target of IgG on astrocytes and/or
microglia can be examined in future studies.
IgG treatment significantly increases tissue preservation
and ameliorates neurobehavioral recovery
Previous studies have reported that attenuation of IL-6
signaling [61,62], blocking neutrophil infiltration
[15,16,39,40,63], or reducing MMP-9 expression [46]
separately after SCI results in tissue preservation and
improvement in hind-limb locomotor function. In this
study, we show that IgG treatment is associated with a
decrease in the area of scar and cavity (Figure 5A), an
increase in tissue sparing (Figure 5B) and a significant
improvement in neurobehavioral recovery (Figure 6A
and B). Importantly, spinal cord axonal conduction
changes (Figure 6C) were in agreement with our neuro-
behavioral outcomes. The results suggest that axonal
conduction is severely impaired following injury and IgG
treatment provides some degree of axonal preservation
or improvement in axonal signaling. This is in agree-
ment with the histological, molecular and behavioral
data. Although the magnitude of tissue preservation in
the IgG-treated animals may appear modest compared
to the saline control group, it has previously been
demonstrated that only 10% of axons are needed to
achieve significant functional recovery after SCI [30].
Our tissue preservation and neurobehavioral findings are
consistent with findings by Gris and colleagues [15], in
which they attenuated leukocyte infiltration with anti-
CD11d antibodies and observed modest levels of tissue
sparing and a two-point improvement in the BBB score
after moderate to severe SCI. In conjunction with other
groups’ findings, our data reinforce the detrimental role
of the acute inflammatory response in SCI. Our results
also support the underlying rationale of immuno-
modulatory therapy in attenuating the effects of the
acute inflammatory response after SCI.
Conclusion
Although a short treatment window of 15 min was
employed in our current study, we have demonstrated
the novel use of IgG in modulating neuroinflammation
and ameliorating neurobehavioral recovery after cervical
SCI in rats. The findings from this study also reinforce
the finding of a detrimental role for the acute inflamma-
tory response. IgG represents a promising immuno-
modulatory agent that reduces inflammation-mediated
damage. IgG is a cost-effective and easily deliverable
therapeutic that could be used in the acute stage of a
combinatorial treatment strategy. Considering there is
currently no effective treatment option for SCI, these
findings could have a significant impact on the treat-
ment of SCI. Before this can be realized, supporting evi-
dence and optimization of efficacy are required. Future
studies will examine a more clinically relevant delayed
time of IgG delivery and establish a dose response.
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